InventisBio (SH:688382)2026-01-29 08:40Financial Projections - The company expects a total profit of -291.82 million yuan for the year 2025, with a net profit attributable to shareholders of -292.20 million yuan, and a net profit of -304.41 million yuan after deducting non-recurring gains and losses [3]. - The projected operating revenue for 2025 is 37.25 million yuan, which is below 100 million yuan [3]. - In 2024, the company reported a total profit of -240.20 million yuan and a net profit attributable to shareholders of -240.20 million yuan [5]. - The operating revenue for 2024 was 168.79 million yuan [7]. Research and Development - The company's R&D investment remains high, with key clinical projects making significant progress, including ongoing Phase III clinical trials for D-0502 and D-2570 [8]. - The company is also advancing two innovative preclinical candidates, YF087 and YF550, which show promising anti-tumor potential [8]. Revenue and Costs - The revenue from technology licensing and cooperation has varied compared to 2024, and is currently insufficient to cover costs and expenses, leading to expected continued losses in 2025 [9]. - The company emphasizes that its core business and competitive strengths have not experienced significant adverse changes despite the projected losses [9]. Financial Reporting - The financial data provided is preliminary and has not been audited by registered accountants, with the final figures to be confirmed in the official audited annual report [10][11].